Unjustified Sell-Off In Achaogen After FDA Panel Vote Provides A Golden Opportunity
Seeking Alpha,
Recently, Achaogen ( AKAO ) had to bring its drug plazomicin up for an FDA advisory panel review.
Recently, Achaogen ( AKAO ) had to bring its drug plazomicin up for an FDA advisory panel review.
Bloodstream infections (BSIs) are frequent in the intensive care unit (ICU) and is a prognostic factor of severe sepsis.